T. Rowe Price Associates
BBOT

T. Rowe Price Associates’s BridgeBio Oncology BBOT Stock Holding History

T. Rowe Price Associates’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Sell
300,000
-137,889
-31% -$1.15M ﹤0.01% 1938
2026
Q1 		$3.92M Sell
437,889
-365,245
-45% -$3.92M ﹤0.01% 1522
2025
Q4 		$10.1M Sell
803,134
-81,908
-9% -$992K ﹤0.01% 1235
2025
Q3 		$10.2M Sell
885,042
-186,508
-17% -$1.94M ﹤0.01% 1222
2025
Q2 		$11.4M Hold
1,071,550
– – ﹤0.01% 1086
2025
Q1 		$12.1M Sell
1,071,550
-16,221
-1% -$174K ﹤0.01% 1074
2024
Q4 		$11.4M Sell
1,087,771
-39,827
-4% -$419K ﹤0.01% 1133
2024
Q3 		$11.8M Sell
1,127,598
-3,079
-0.3% -$31.8K ﹤0.01% 1112
2024
Q2 		$11.6M Hold
1,130,677
– – ﹤0.01% 1087
2024
Q1 		$11.7M Buy
+1,130,677
New +$11.7M ﹤0.01% 1077

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Associates's BBOT Position: Q2 2026 in Review

T. Rowe Price Associates reduced its BridgeBio Oncology (BBOT) stake by 31% in Q2 2026, selling an estimated $1.15M and leaving 300,000 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

T. Rowe Price Associates first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.1M in Q1 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • T. Rowe Price Associates held 300,000 shares of BridgeBio Oncology worth $2.29M as of Q2 2026.
  • T. Rowe Price Associates sold 137,889 BridgeBio Oncology shares in Q2 2026, an estimated $1.15M.
  • BridgeBio Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1938 holding.
  • T. Rowe Price Associates first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
  • T. Rowe Price Associates's BridgeBio Oncology position peaked at $12.1M in Q1 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.